MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$4,836K
EPS
-$0.32
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
-
-
30,193*
-
Commercialization revenue
630
516
-
3,453
Cost of commercialization revenue
191
124
20,209*
115
Research and development expenses
1,345
164
-36,945*
2,925
General and administrative expenses
3,814
3,597
10,502*
3,987
Total costs and operating expenses
5,350
3,885
-6,235*
7,027
Income (loss) from operations
-4,720
-3,369
36,428*
-3,574
Interest income
78
54
163*
204
Interest expense
191
830
971*
909
Other income (expense), net
0
0
-73*
4
Total other income (expense), net
-113
-776
-881*
-701
Income (loss) before provision for (benefit from) income taxes
-4,833
-4,145
35,547*
-4,275
Provision for (benefit from) income taxes
1
0
-15*
28
Net income (loss)
-4,834
-4,145
35,562*
-4,303
Unrealized gain (loss) on available-for-sale securities
-2
-1
-10*
2
Comprehensive income (loss)
-4,836
-4,146
35,552
-4,301
Basic EPS
-0.32
-0.29
2.995
-0.32
Diluted EPS
-0.32
-0.29
2.895
-0.32
Basic Average Shares
15,033,000
14,081,000
11,871,000
13,564,000
Diluted Average Shares
15,033,000
14,081,000
12,280,000
13,564,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive income (loss)
-$4,836K
(-302.60%↓ Y/Y)
Net income (loss)
-$4,834K
(-302.51%↓ Y/Y)
Unrealized gain (loss) on
available-for-sale securities
-$2K
Income (loss) before
provision for (benefit...
-$4,833K
(-302.22%↓ Y/Y)
Provision for (benefit
from) income taxes
$1K
(-66.67%↓ Y/Y)
Income (loss) from
operations
-$4,720K
(-247.64%↓ Y/Y)
Total other income
(expense), net
-$113K
(86.00%↑ Y/Y)
Commercialization revenue
$630K
(-96.42%↓ Y/Y)
Interest income
$78K
(-45.45%↓ Y/Y)
Total costs and
operating expenses
$5,350K
(-62.79%↓ Y/Y)
Interest expense
$191K
(-80.35%↓ Y/Y)
General and
administrative expenses
$3,814K
(-41.45%↓ Y/Y)
Research and development
expenses
$1,345K
(-81.60%↓ Y/Y)
Cost of
commercialization revenue
$191K
(-65.52%↓ Y/Y)
Buy us a coffee
Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. (ATRA)